Eric J Dziuban
Overview
Explore the profile of Eric J Dziuban including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
436
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huong P, Nguyen A, Nhan D, Dziuban E, Pollack T
Lancet HIV
. 2025 Feb;
12(3):e170-e172.
PMID: 39956127
No abstract available.
2.
Dang M, Le Y, Naz-McLean S, Vo N, Do P, Doan L, et al.
BMC Infect Dis
. 2024 Dec;
24(1):1462.
PMID: 39722011
Background: Long-acting injectable antiretrovirals (LAI-ARVs) for HIV prevention and treatment have been demonstrated in clinical trials to be non-inferior to daily oral medications, providing an additional option to help users...
3.
Bekele A, Hrapcak S, Mohammed J, Yimam J, Tilahun T, Antefe T, et al.
BMC Pediatr
. 2022 Dec;
22(1):736.
PMID: 36572846
Background: Successful linkage to HIV services and initiation of antiretroviral treatment (ART) for children living with HIV (CLHIV) is critical to improve pediatric ART coverage. We aimed to assess confirmatory...
4.
Smith-Sreen J, Miller B, Kabaghe A, Kim E, Wadonda-Kabondo N, Frawley A, et al.
Emerg Infect Dis
. 2022 Dec;
28(13):S93-S104.
PMID: 36502398
We used publicly available data to describe epidemiology, genomic surveillance, and public health and social measures from the first 3 COVID-19 pandemic waves in southern Africa during April 6, 2020-September...
5.
So M, Dziuban E, Pedati C, Holbrook J, Claussen A, OMasta B, et al.
Prev Sci
. 2022 Aug;
25(Suppl 2):316-336.
PMID: 35947281
Although neurobiologic and genetic factors figure prominently in the development of attention deficit/hyperactivity disorder (ADHD), adverse physical health experiences and conditions encountered during childhood may also play a role. Poor...
6.
Teferi W, Gutreuter S, Bekele A, Ahmed J, Ayalew J, Gross J, et al.
BMC Infect Dis
. 2022 May;
22(1):480.
PMID: 35596158
Background: Implementing effective and efficient case-finding strategies is crucial to increasing pediatric antiretroviral therapy coverage. In Ethiopia, universal HIV testing is conducted for children presenting at high-risk entry points including...
7.
Jordan M, Bikinesi L, Ashipala L, Mutenda N, Brantuo M, Hunt G, et al.
Open Forum Infect Dis
. 2022 Apr;
9(5):ofac102.
PMID: 35434174
Background: The World Health Organization (WHO) recommends routine surveillance of pretreatment human immunodeficiency virus (HIV) drug resistance (HIVDR) in children <18 months of age diagnosed with HIV through early infant...
8.
Korn A, Muzingwani L, OBryan G, Ensminger A, Boylan A, Kafidi E, et al.
PLoS One
. 2022 Feb;
17(2):e0263920.
PMID: 35171941
The aim of this study was to assess differences in cervical cancer screening and treatment outcomes by HIV status in a routine programmatic setting with a high generalized HIV prevalence....
9.
Hrapcak S, Bekele A, Ahmed J, Ayalew J, Gutreuter S, Kumssa H, et al.
Pediatr Infect Dis J
. 2021 Oct;
40(12):1090-1095.
PMID: 34609102
Background: Limited data in low HIV prevalence settings such as Ethiopia limit policy development and implementation of optimized pediatric testing approaches to close the treatment gap. This study aimed to...
10.
Nyarko K, Miller L, Baughman A, Katjiuanjo P, Evering-Watley M, Antara S, et al.
BMJ Glob Health
. 2021 Apr;
6(4).
PMID: 33849899
Namibia faces a critical shortage of skilled public health workers to perform emergency response operations, preparedness activities and real-time surveillance. The Namibia Field Epidemiology and Laboratory Training Programme (NamFELTP) increases...